anti human C4d (FITC-Conjugated)
$842.00
Catalog
04-BI-RC4D-FITC
The anti human C4d (FITC-Conjugated) antibody detects human complement split product C4d and has been tested for FACS Application.
Regulatory Status
Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available in North America Only
Inc Time Overnight
No
Inc Time See Protocol
No
Quantity
100
Quantity UOM
µL/vial
Circulating alloantibodies encounter the grafted endothelium as the first target. Living endothelial cells can rapidly eliminate bound antibodies from the cell surface by “capping”, “shedding” or “internalization”.
C4d is the degradation product of the activated complement factor C4, a component of the classical complement cascade, which is typically initiated by binding of antibodies to specific target molecules. Detection of C4d is regarded as an indirect sign, a “footprint” of an antibody response against the allograft. Many publications describe C4d as an important
biomarker in kidney transplantation but also in heart, liver, and other transplants.